miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica

View original at globenewswire.com
Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Biosimilars in oncology generated USD 7 billion in savings for payers in 2023/2024, with cumulative savings reaching USD 19 billion since 2017

    80% confidence

  • The global oncology clinical trials market is projected to hit the market valuation of USD 25.61 billion by 2035 from USD 14.95 billion in 2025 at a CAGR of 5.53% during the forecast period 2026–2035

    80% confidence

  • A 160% increase in pancreatic cancer survival rates was reported in 2024 due to clinical trial advancements

    80% confidence

  • Spending on cancer medicines will reach USD 441 billion by 2029

    80% confidence

  • Novel modalities, including ADCs and Cell/Gene therapies, accounted for 35% of all oncology trial starts in 2024

    80% confidence

  • Asia-Pacific is projected to witness the fastest CAGR from 2025 to 2034

    80% confidence

  • The probability of technical success for ADC monotherapies in Phase III is 53%, higher than the general oncology average

    80% confidence

  • The number of oncology Novel Active Substances (NAS) launched globally in the 5-year period ending 2024 reached 132

    80% confidence

  • North America accounted for over 41.58% revenue share of the oncology clinical trials market

    80% confidence

  • 2,162 oncology clinical trials were initiated globally in 2024, representing a 12-unit increase on an index basis compared to 2019 levels

    80% confidence

  • Global spending on cancer medicines reached USD 252 billion in 2024, reflecting a USD 29 billion increase from the previous year

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · drug approvals17 drugs
U.S. Food and Drug Administration · approval decisions32 decisions
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica — Source | Via News | es.VIA.NEWS